Only a few dozen patients with lupus have been treated with CAR-T-cell therapy — but in a small German study, all five ...

To make the therapy safer and more adaptable, UChicago researchers developed a new “split” system called GA1CAR. This uses ...

T cell therapies have revolutionized cancer treatment—but so far, their success has been largely limited to blood cancers.

By Michael Le PageImmune cells that have been genetically engineered to kill cancerous cells, known as CAR T-cells, have ...

Kyverna saw an 8-point improvement on the MG-ADL scale, which measures the impact of gMG on daily functions, in the three ...

First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory ...

CD19 chimeric antigen receptor T-cell therapy improved lung function and skin thickness in patients with severe refractory systemic sclerosis, with 96% remaining off SSc treatment during follow-up, ...

Community-based CAR T-cell therapy improves access, reducing travel burdens and hospital admissions for patients with blood ...

With a 100% response rate in a Phase II study, KYV-101 sets a new efficacy bar in generalized myasthenia gravis, according to ...

Patients relapsing within three months post-CAR T-cell therapy have lower response rates to BsAb therapy compared to those relapsing after six months. Elevated LDH levels and higher international ...

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international phase 1/2 clinical trial led ...

Discover how CAR T cell therapy is breaking new ground in treating Multiple Sclerosis for the first time in the UK ...